6533b7d3fe1ef96bd125feca

RESEARCH PRODUCT

An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).

Giovanni GrignaniAngela BuonadonnaGiuseppe BadalamentiEmanuela MarchesiAntonio PizzorussoElisabetta SetolaEmanuela PalmeriniTommaso De PasAlessandro ComandoneIrene QuattriniAntonella BrunelloPaolo G. CasaliPiero PicciToni IbrahimStefano FerrariVirginia FerraresiLaura MilesiBruno VincenziFederica GrossoGabriele Luppi

subject

OncologyCancer Researchmedicine.medical_specialtyIfosfamidebusiness.industrySoft tissue sarcomaRetrospective cohort studymacromolecular substancesmedicine.diseasecarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicineotorhinolaryngologic diseasesbacteriaMedicineObservational studyIn patientSarcomabusinessTrabectedinmedicine.drug

description

e23502Background: Trabectedin (T) is approved for patients (pts) with STS after failure of anthracyclines (A) and ifosfamide (I), or pts unsuited to receive AI. ISG performed a retrospective study ...

https://doi.org/10.1200/jco.2018.36.15_suppl.e23502